AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04099992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS)
Description: Transcutaneous Vagus Nerve Stimulation (tVNS) is delivered using gammaCore (Electrocore), a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
Study NCT04099992 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-transcutaneous Vagus Nerve Stimulation (tVNS)
Description: Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
Study NCT02619357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear Armband Gecko
Description: Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
Study NCT02619357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear Armband MF
Description: Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
Study NCT02619357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph GT9x wristband and waistband
Description: Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
Study NCT03195257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
Study NCT02619357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Garmin Vivofit 2 wristband
Description: Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
Study NCT02619357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMNOwatch plus EEG 6 sleep monitor
Description: In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
Study NCT02619357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercises
Description: Subjects will perform strength exercises using elastic bands of varying resistance
Study NCT02619357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Field-based exercise tests
Description: Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
Study NCT02619357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory-based exercise tests
Description: Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
Study NCT00289419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Ropivacaine, morphine
Description: Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
Study NCT00289419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine, Ketorolac and Adrenaline
Description: Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
Study NCT01870011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane balanced anesthesia
Description: Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
Study NCT01870011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol total intravenous anesthesia
Description: Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
Study NCT04597177 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ST-IMRT SW-IMRT
Study NCT04597177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ST-IMRT SW-IMRT
Study NCT03194633 — intervention group
Intervention type: DRUG
Intervention: Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)
Description: Nifedipine GITS 60 mg (once per day)
Study NCT00623168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 7 Day multiple dosing regime based on weight and dosage day
Study NCT01767766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 Daily Oral Dose
Study NCT02792062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 40 mg
Description: TAK-385 40 mg tablet
Study NCT03208998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study NCT00672724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
Study NCT00672724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
Study NCT01317888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAB-425 radiolabeled with I-125
Description: MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
Study NCT02159053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
Study NCT02159053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
Study NCT02159053 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
Study NCT02027454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
Study NCT02027454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 matching placebo
Description: GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
Study NCT02027454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
Study NCT03195257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
Study NCT03195257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
Study NCT02862106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: εPA-44
Description: subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
Study NCT02322957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: Subjects will be randomized to one of two treatment sequences: AB or BA.
Study NCT04987515 — intervention group
Intervention type: PROCEDURE
Intervention: fenestration decompression combined with secondary curettage
Description: First，fenestration decompression was performed. then, patients return every 3 months for follow up. If the cystic cavity area was gradually reduced after one year of follow-up, patients should be considered for secondary curettage surgery.
Study NCT01990469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Description: DPP-4 inhibitor
Study NCT01990469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemigliptin placebo
Description: Placebo of Gemigliptin
Study NCT00245895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aranesp
Description: Aranesp
Study NCT01603069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD3241 300 mg BID
Description: The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
Study NCT01603069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD3241 600 mg BID
Description: The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
Study NCT01603069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AZD3241 BID
Study NCT01358968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously as a 1-hour infusion.
Study NCT01358968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Administered orally
Study NCT01358968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously as a 10-minute infusion.
Study NCT01358968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously as a 30-minute infusion.
Study NCT01021202 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous dilation tracheostomy
Description: Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
Study NCT04022668 — intervention group
Intervention type: RADIATION
Intervention: Coronary angiogram
Description: Routine coronary angiogram, if indicated
Study NCT02817295 — intervention group
Intervention type: OTHER
Intervention: clinical measurements
Description: follow up on the number of complications, revisions, hospitalization and co-morbidities
Study NCT01775813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
Study NCT01775813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
Study NCT03809663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Solution for injection
Study NCT03809663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection
Study NCT01029782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV cefazolin plus oral probenecid and placebo cephalexin
Description: Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
Study NCT01029782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cephalexin and saline IV plus probenecid placebo
Description: Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
Study NCT00931255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: 3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
Study NCT00931255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: 5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
Study NCT03189095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOWii (Workout on Wheels Internet Intervention)
Description: Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers.
Study NCT04445038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610
Description: Recombinant anti-IL-5 Humanized Monoclonal Antibody
Study NCT04445038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01739231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE527
Description: 3x10\^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II \[CS1, CS2, CS3\] and CFA/IV \[CS5, CS6\]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~* ACAM2025: a live, attenuated, CFA/I, LTB positive strain~* ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~* ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain.
Study NCT01739231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dmLT
Description: A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
Study NCT01739231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CeraVacx placebo
Description: CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
Study NCT01739231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H10407 challenge strain
Description: Approximately 2 x 10\^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
Study NCT01739231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H10407 challenge strain
Description: Approximately 2 x 10\^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
Study NCT05670665 — intervention group
Intervention type: OTHER
Intervention: Threatened preterm labor
Description: Presence of uterine contractions and cervical shortening between 24+0 and 36+6 weeks of gestation and/or rupture of the membranes between 24+0 and 36+6 weeks of gestation.
Study NCT03540316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Two short implants and 2 minutes LLLT
Description: Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
Study NCT03540316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Two short implants and 4 minutes LLLT
Description: Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
Study NCT03540316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Four short implants and 2 minutes LLLT
Description: Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
Study NCT03540316 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Four short implants and 4 minutes LLLT
Description: Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
Study NCT02289248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects will undergo a twice weekly two week course of IV infusions of ketamine
Study NCT02289248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Subjects will undergo twice weekly CBT for a total of 8 weeks
Study NCT00757042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Administered by subcutaneous or intravenous injection
Study NCT00757042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered by subcutaneous or intravenous injection.
Study NCT01715532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huachansu
Study NCT01715532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TACE
Study NCT01715532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Study NCT01421680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure powder
Description: Ensure powder(500kcal) per day for 7 weeks
Study NCT04423744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: Film-coated tablet
Study NCT04423744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet
Study NCT04423744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo as film-coated tablet
Study NCT02964520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Description: uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
Study NCT02964520 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham comparator: Sham neurofeedback training
Description: in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
Study NCT01598493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCT Antimicrobial Dressing
Description: Activated carbon fiber impregnated with silver particles